0001683168-21-003827.txt : 20210820
0001683168-21-003827.hdr.sgml : 20210820
20210820203645
ACCESSION NUMBER: 0001683168-21-003827
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210810
FILED AS OF DATE: 20210820
DATE AS OF CHANGE: 20210820
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Liquard Thomas
CENTRAL INDEX KEY: 0001879094
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40699
FILM NUMBER: 211195084
MAIL ADDRESS:
STREET 1: C/O PHARMACYTE BIOTECH INC.
STREET 2: 23046 AVENIDA DE LE CORLOTA
CITY: LAGUNA HILLS
STATE: CA
ZIP: 92653
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PharmaCyte Biotech, Inc.
CENTRAL INDEX KEY: 0001157075
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 621772151
STATE OF INCORPORATION: NV
FISCAL YEAR END: 0430
BUSINESS ADDRESS:
STREET 1: 23046 AVENIDA DE LA CARLOTA, SUITE 600
CITY: LAGUNA HILLS
STATE: CA
ZIP: 92653
BUSINESS PHONE: (917) 595.2850
MAIL ADDRESS:
STREET 1: 23046 AVENIDA DE LA CARLOTA, SUITE 600
CITY: LAGUNA HILLS
STATE: CA
ZIP: 92653
FORMER COMPANY:
FORMER CONFORMED NAME: NUVILEX, INC.
DATE OF NAME CHANGE: 20090324
FORMER COMPANY:
FORMER CONFORMED NAME: EFOODSAFETY COM INC
DATE OF NAME CHANGE: 20010808
3
1
ownership.xml
X0206
3
2021-08-10
0
0001157075
PharmaCyte Biotech, Inc.
PMCB
0001879094
Liquard Thomas
23046 AVENIDA DE LA CARLOTA
SUITE 600
LAGUNA HILLS
CA
92653
1
0
0
0
Common Stock
1667
D
Stock Option (right to buy)
156.00
2017-03-09
2022-03-09
Common Stock
167
D
Stock Option (right to buy)
87.00
2017-07-03
2022-07-03
Common Stock
167
D
Stock Option (right to buy)
80.85
2018-05-01
2023-05-01
Common Stock
334
D
Stock Option (right to buy)
60.60
2019-05-01
2024-05-01
Common Stock
334
D
Stock Option (right to buy)
36.00
2020-05-01
2025-05-01
Common Stock
334
D
Stock Option (right to buy)
26.55
2021-05-01
2026-04-30
Common Stock
334
D
The number of shares has been adjusted to reflect a one-for-1,500 reverse stock split of the Issuer's common stock effected on July 12, 2021 (the "Reverse Split").
The exercise price has been adjusted to reflect the Reverse Split.
/s/ Thomas Liquard
2021-08-20